Shukra Pharmaceuticals Limited (SHUKRAPHAR) Financial History

Name: Shukra Pharmaceuticals Limited (SHUKRAPHAR) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Shukra Pharmaceuticals Limited (SHUKRAPHAR) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Ahmedabad, India. Its market capitalization is roughly ₹25 billion. In the fiscal year ended 2026-03-31, SHUKRAPHAR reported ₹567M in revenue and ₹221M in net income.

Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally.

Interactive charts & full statements →

SHUKRAPHAR Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹567M	₹326M	₹746M	₹588M	—
Gross Profit	₹409M	₹245M	₹301M	₹135M	—
Operating Income (EBIT)	₹253M	₹97M	₹174M	₹35M	—
Net Income	₹221M	₹96M	₹185M	₹44M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SHUKRAPHAR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹235M	₹63M	₹391M	₹59M	₹54M	—
Gross Profit	₹251M	₹4M	₹320M	₹39M	₹46M	—
Operating Income (EBIT)	₹181M	(₹3M)	₹263M	(₹12M)	₹5M	—
Net Income	₹130M	(₹17M)	₹204M	₹24M	₹10M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SHUKRAPHAR Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹4M)	(₹44M)	(₹1M)	(₹1M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SHUKRAPHAR Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹1.2B	₹868M	₹778M	₹750M	—
Total Liabilities	₹276M	₹239M	₹202M	₹497M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SHUKRAPHAR viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

HIKAL · Hikal Limited — ₹28 billion
3320 · China Resources Pharmaceutical Group Limited — HK$27 billion
0867 · China Medical System Holdings Limited — HK$27 billion
SAKAR · Sakar Healthcare Limited — ₹26 billion
INDOCO · Indoco Remedies Limited — ₹23 billion
WINDLAS · Windlas Biotech Limited — ₹23 billion
FREDUN · Fredun Pharmaceuticals Limited — ₹22 billion
6887 · Sunshine Lake Pharma Co., Ltd. — HK$21 billion

← SHTU All “S” companies SHUS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.